mapping the effectiveness and risks of glp-1 receptor agonists mapping the effectiveness and risks

Research on humans is still underway, but the results so far are promising

Use of GLP-1RA is protective and prevents bone fractures over a longer period of use in T2DM patients in a recent trial in 2020 liraglutide showed to have decreased bone resorption compared to placebo (120)

Analyst 138:31423145

No effects on blood sugar, insulin levels, or IGF-1 were observed

Acquired melanocytic nevus is not present at birth, and the incidence increases throughout the first three decades of life

This has raised the interest among insurance companies, given the ability of GGT to serve as a correlate of an increased risk of mortality [24]